A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Aldeyra Therapeutics

Status and phase: Completed; Phase 3

Conditions: Dry Eye Disease

Treatments: Drug: Reproxalap Ophthalmic Solution (0.25%); Drug: Placebo Comparator

Study type: Interventional

Funder types: Industry

Identifiers

NCT04735393

ADX-102-DED-021

Details and patient eligibility

About

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease

Enrollment: 757 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age (either gender and any race);
• Reported history of dry eye for at least 6 months prior to Visit 1;
• History of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1.

Exclusion criteria

• Clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
• Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
• Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial;
• Eye drop use within 2 hours of Visit 1;
• Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
• Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution within 90 days of Visit 1;
• Planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
• Temporary punctal plugs during the study that have not been stable within 30 days of Visit 1.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

757 participants in 4 patient groups, including a placebo group

Reproxalap (0.25%) for six weeks

Experimental group

Description:

Reproxalap four times daily (QID) for four weeks followed by two times daily (BID) for two weeks

Treatment:

Drug: Reproxalap Ophthalmic Solution (0.25%)

Drug: Reproxalap Ophthalmic Solution (0.25%)

Vehicle for six weeks

Placebo Comparator group

Description:

Vehicle QID for four weeks followed by BID for two weeks

Treatment:

Drug: Placebo Comparator

Drug: Placebo Comparator

Reproxalap (0.25%) for 12 months

Experimental group

Description:

Reproxalap (0.25%) QID for four weeks followed by BID for 11 months

Treatment:

Drug: Reproxalap Ophthalmic Solution (0.25%)

Drug: Reproxalap Ophthalmic Solution (0.25%)

Vehicle for 12 months

Placebo Comparator group

Description:

Vehicle QID for four weeks followed by BID for 11 months

Treatment:

Drug: Placebo Comparator

Drug: Placebo Comparator